Henriëtte M. de Jong

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis

Janneke J. de Winter, Jacqueline E Paramarta, Henriëtte M. de Jong et al. · RMD Open · 2019 · 64 citations · Full text

Brief Report: Interleukin‐17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses

Leonieke van Mens, M. G. H. Van de Sande, Silvia Menegatti et al. · Arthritis & Rheumatology · 2018 · 51 citations

Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate

Leonieke van Mens, Henriëtte M. de Jong, Inka A. Fluri et al. · Annals of the Rheumatic Diseases · 2019 · 48 citations · Full text

IL-12p40/IL-23p40 Blockade With Ustekinumab Decreases the Synovial Inflammatory Infiltrate Through Modulation of Multiple Signaling Pathways Including MAPK-ERK and Wnt

Renée H. Fiechter, Henriëtte M. de Jong, Leonieke van Mens et al. · Frontiers in Immunology · 2021 · 29 citations · Full text

Patients’ and rheumatologists’ perceptions on preventive intervention in rheumatoid arthritis and axial spondyloarthritis

Laurette van Boheemen, Janne W. Bolt, Marieke M. ter Wee et al. · Arthritis Research & Therapy · 2020 · 17 citations · Full text